ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Phase C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment right up until illness progression or maybe the participants are not able to tolerate the study drugs.Feasible new approaches with the prognosis and treatment of AML. (A) The identificat